It is also FDA approved for BRAF V600 mutation–positive unresectable or metastatic melanoma, metastatic non–small cell lung cancer (NSCLC) and disease progression on or after platinum-based therapy, advanced renal cell carcinoma (RCC) after receiving prior antiangiogenic therapy, classical Hodgkin lymphoma (HL) that has relapsed or progressed after autologous hematopoietic stem cell transplant and posttransplantation brentuximab vedotin (Adcetris), and recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after a platinum-based therapy. Here, BRAF is linked to Hodgkins lymphoma.